Dupilumab

/Dupilumab

Dupilumab – Hocum

By | April 3rd, 2018|Dupilumab|

"VERY INTERESTING" This was the often used comment by Arte Johnson on the decades old 'Laugh In' show on NBC television. He played a German spy or professor with a strong German accent and used this comment when things appeared very peculiar to him. I repeat the same comment when I quote a Dr Andrew [...]

Dupilumab: More Peculiar Happenings

By | March 28th, 2018|Dupilumab|

Here's a new comment on Dupilumab. Patient 1: A 20ish healthy male with life-long use of steroids for eczema and with resultant RSS is admitted to the hospital for nearly 4 weeks to have various forms and strengths of steroid creams and oral medication to be applied to the whole body. Then, once he is [...]

Prescribing Dupilumab

By | March 25th, 2018|Dupilumab|

Something is peculiar with the new drug Dupilumab and its marketing. Patient 1 - a moderately symptomatic RSS patient, functioning fairly well, received a near 3 page letter from his dermatologist to take the new 'wonder drug' Dupilumab. The letter contained all kinds of compliments for the drug and the doctor has probably had little [...]

Dupilumab

By | March 7th, 2018|Dupilumab, RSS Patients|

Some thoughts about Dupilumab We all need input from patients who have been taking or took the drug. Information on patients on the drug has not been forthcoming. Tell us if you have had good results or no results. Yes, this is anecdotal, but we need some direction. The drug is extremely expensive - why? [...]

Dupilumab Study – Subject Patient Comments

By | April 6th, 2017|Dupilumab|

The Dupilumab studies were 16 weeks long. This is a very short time to truly evaluate a drug in this very difficult and prolonged skin problem. In addition, there were no objective comments on rash, redness, skin oozing, edema and pain. There are no long term follow ups reported. But: Links to patient comments after [...]

Dupilumab Study – Are Eczema Patients Being ‘duped’ Again?

By | April 4th, 2017|Dupilumab|

My most recent postings have dissected the protocol, the patients, the methods and the fine print of the Dupilumab studies reported in the medical literature. Severe failings are evident in all the above criteria. What, therefore can we expect from the results and conclusions? This assessment will group together all Dupilumab studies. My findings are: [...]

Dupilumab – Does the Drug Work?

By | April 3rd, 2017|Dupilumab|

The Dupilumab studies as reported in the New England Journal of Medicine and the Journal of the American Academy of Dermatology and by me on discussed in my four prior posts exhibit multiple violations in the study of new drugs and scientific reporting. Inclusion of patients: from my experience with 4000 totally similar patients none [...]

Dupilumab – Horror Movie

By | March 31st, 2017|Dupilumab|

In recounting the diagnosis, management and cure of 4000 corticosteroid addicted atopic dermatitis patients I feel like I am in a futuristic movie with a split screen simultaneously showing two similar populations. One population is now in the present consisting of suffering patients who go on to CURE – albeit through a prolonged period of [...]

Dupilumab Study – Journal Articles

By | March 30th, 2017|Dupilumab|

Dupilumab is now FDA approved as of March 28, 2017 and this event necessitates a further evaluation for the prospects of this drug helping eczema patients. Physicians and patients are being told the published results but they deserve an objective critique. There are multiple discrepancies and violations of true, honest research and in looking at [...]

Dupilumab: Further Comments

By | March 28th, 2017|Dupilumab|

After having cured 4000 plus patients with steroid addiction and Red Skin Syndrome, I feel duty bound to offer sound advice to those still mismanaged suffering patients still floundering in their care. In that regard I look at every new drug offering promise of improvement or cure to these patients. I dissect the quality of [...]